Sirolimus
Rapamune · mTOR inhibitor
Proteinuria, cast nephropathy, delayed graft recovery.
Antibody-drug conjugate (TROP2/DXd)
Datroway · DatoDXd
Antibody-drug conjugate (TROP2/DXd) · approved 2025 · 6 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A 2025 TROP2 deruxtecan ADC — proximal-tubular risk extrapolated from the ADC class.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Renal signal is theoretical and not yet quantified, extrapolated from the ADC class. In TROPION-PanTumor01 and the phase III TROPION-Breast01 the dominant toxicities were mucosal (stomatitis ~50%) and ocular events, nausea, and interstitial lung disease; grade ≥3 treatment-related adverse events were lower than chemotherapy (~21%), and kidney-specific events were not prominent.Source: Bardia et al., J Clin Oncol 2024 (TROPION-Breast01)
Not well characterized given recent approval, but by class analogy a subacute tubular pattern emerges during cumulative dosing.
Distilled from: “Not well characterized (recent approval); by class analogy a subacute tubular pattern during cumulative dosing.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
TROP2 (trophoblast cell-surface antigen 2)-directed antibody-drug conjugate; a humanized anti-TROP2 IgG1 linked via a cleavable tetrapeptide linker to the topoisomerase-I inhibitor payload deruxtecan (DXd, an exatecan derivative). After TROP2 binding and internalization the payload is released and kills the target cell with membrane-permeable bystander activity. Approved for TROP2-expressing HR+/HER2− breast cancer and EGFR-mutant NSCLC.
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Class-level context for the major non-renal toxicities of the Antibody-drug conjugate (TROP2/DXd) class.
Hematologic
Cytopenias, thrombosis, TMA
Ophthalmic
Keratopathy, uveitis, retinopathy
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (May 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Monitor patients with renal impairment for increased adverse reactions, including respiratory reactions. A higher incidence of ILD/pneumonitis has been observed in patients with creatinine clearance (CLcr) 30 to <90 mL/min (estimated by Cockcroft Gault) [see Warnings and Precautions (5.1) ]. No dosage adjustment is recommended in patients with CLcr 30 to <90 mL/min [see Clinical Pharmacology (12.3) ] . The pharmacokinetics of datopotamab deruxtecan-dlnk or DXd in patients with CLcr <30 mL/min is unknown.
Kidney rows of the label's dosage tables
From the DATROWAY label (May 2026) · DailyMed
No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 859 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
173 of 859 reports
Reported with hospitalization
137 of 859 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Datopotamab deruxtecan (Dato-DXd) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Rapamune · mTOR inhibitor
Proteinuria, cast nephropathy, delayed graft recovery.
Emrelis · c-Met ADC (MMAE)
c-Met MMAE antibody-drug conjugate; proximal tubular ATN risk extrapolated from the ADC/MMAE class.
Boniva · Bisphosphonate
Lower renal risk than zoledronate.
Padcev · Antibody-drug conjugate (Nectin-4/MMAE)
Emerging AKI and electrolyte signals in urothelial cancer.
Enhertu · Antibody-drug conjugate (HER2/DXd)
Emerging AKI/proteinuria reports — under-published.
Pepaxto · Peptide-conjugated alkylator
Delivers melphalan intracellularly; BRIDGE supports a reduced 30 mg dose in moderate renal impairment.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.